Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 15 clinical trials
Featured trial
Verismo: AN OBSERVATIONAL STUDY OF OCRELIZUMAB-TREATED PATIENTS WITH MULTIPLE SCLEROSIS TO DETERMINE THE INCIDENCE AND MORTALITY RATES OF BREAST CANCER AND ALL MALIGNANCIES

The purpose of this study is to obtain additional safety information on OCREVUS® and to gain insights about how well OCREVUS® is tolerated by patients to whom it is prescribed in routine practice.

ocrelizumab
  • 0 views
  • 08 Jan, 2022
  • 1 location
Featured trial
A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

A 12-month, Randomized, Rater- and Dose-blinded Study to Compare the Efficacy and Safety of Fingolimod 0.25 mg and 0.5 mg Administered Orally Once Daily With Glatiramer Acetate 20 mg Administered Subcutaneously Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

  • 211 views
  • 25 Mar, 2021
  • 1 location
Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis

The DanNORMS study is phase 3 non-inferiority clinical trial examining whether treatment of active multiple sclerosis with rituximab is non-inferior to ocrelizumab regarding efficacy and safety

ocrelizumab
disease or disorder
MRI
methylprednisolone
myelopathies
  • 0 views
  • 01 Dec, 2021
  • 12 locations
Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease

This is a multicenter non-inferiority study, designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients

  • 0 views
  • 25 Mar, 2021
  • 11 locations
Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset

Newly diagnosed relapsing multiple sclerosis (MS) and high risk clinically isolated syndrome (CIS) patients will be treated with ocrelizumab at disease onset to see if treatment favorably alters

  • 0 views
  • 26 Jan, 2021
  • 1 location
Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714

Ocrelizumab is a humanized anti-CD20 monoclonal antibody that showed in phase III trials a powerful effect on relapse rate and lesion load accumulation in the relapsing form of multiple

chronic progressive multiple sclerosis
myelopathies
secondary progressive multiple sclerosis
natalizumab
ocrelizumab
  • 2 views
  • 24 Jan, 2021
  • 1 location
Ocrelizumab or Alemtuzumab Compared With Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis - a Phase-2 Randomised Controlled Trial

A multicentre controlled phase II trial to compare the efficacy and safety of ocrelizumab or alemtuzumab and autologous Hematopoietic Stem Cell Transplantation (aHSCT). Active relapsing

ocrelizumab
disease or disorder
alemtuzumab
  • 0 views
  • 10 Oct, 2021
  • 2 locations
Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multiple Sclerosis

short course of treatment with B-cell depleting antibody (ocrelizumab), will be safe and equally effective in reducing MS disease activity (as compared to patients receiving continuous treatment with

ocrelizumab
disease or disorder
MRI
nervous
myelopathies
  • 0 views
  • 18 Oct, 2021
  • 1 location
Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive Rehabilitation

Given that up to 70% of people with secondary progressive MS are cognitively impaired, the search for effective treatments is considered a priority by people living with the disease. This proposal will address the effectiveness of cognitive rehabilitation (CR) and exercise, either alone, or in combination in this regard. A …

  • 0 views
  • 26 Jan, 2021
  • 1 location
Specific Anti-HBV Vaccine Response After Vaccination in Patients Requiring Anti-CD20 Monoclonal Antibodies

Vaccination coverage against HBV in France is around 30% in the adult population. Treatment with anti-CD20 is associated with a risk of reactivation of hepatitis B or acute or fulminant hepatitis in first-infected patients. HBV vaccination is recommended as before any anti-CD20 treatment in unimmunized patients. However, there is no …

  • 0 views
  • 12 Feb, 2021
  • 1 location